Press Releases

2008	Topic
31 March	Announces Start of Ph II Efficacy Trial for Rufinamide SYN-111 [pdf]
4 February	Appoints Chief Financial Officer to New Company Headquarters in Switzerland [pdf]
22 January	Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug Rufinamide [pdf]
2007	Topic
13 December	Appoints Chief Business Officer to lead Swiss office [pdf]
5 November	Appoints Vice President of Clinical Research and Development to Swiss office [pdf]
15 October	Establishes Scientific Advisory Board [pdf]
18 June	Appoints Vice President of Regulatory Affairs [pdf]
22 May	New Agreement With Syngenta Boosts Pipeline [pdf]
16 May	Appoints New Chief Medical Officer [pdf]
23 April	Synosia Therapeutics Announces Second Major Pharmaceutical Deal [pdf]
23 March	Synosis Therapeutics Changes Name to Synosia Therapeutics [pdf]
4 January	Roche and Synosis Therapeutics announce partnership to explore potential of five compounds targeting the central nervous system. See full press release [pdf]

Media inquiries

Julie Walters
Tudor Reilly (Europe)
Tel: +44 (0) 20 7016 7714
Fax: +44 (0) 20 7408 9456
Mobile: +44 (0) 775 3626967
Email: julie.walters@tudor-reilly.com

Michele Parisi
Tudor Reilly (US)
Tel: +1 925 864 5028
Email: michele.parisi@tudor-reilly.com